๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jingzhou
Clinical trial register · China

Clinical Trials in Jingzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sanofi4 Renmin Hospital of Wuhan University2 Bristol-Myers Squibb2 Dongmei Huang1 Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.1
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jingzhou

26 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
NCT07741448UTUC
DrugsTrastuzumab Rezetecan·Gemcitabine
Zhiquan Hu
Phase 2
54
Huanggang, Jingzhou, Shiyan, Wuhan, Xiangyang, Yichang
2026-08-15
Not yet open
A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer
NCT07653685Colorectal Cancer
DrugsTQB2930·Oxaliplatin·Capecitabine·Bevacizumab
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
71
Beijing, Lanzhou, Nanning, Zunyi, Harbin, Zhengzhou, Jingzhou, Wuhan
2026-07
Recruiting
Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases
NCT07595068Atrial Fibrillation (AF), Cardiovascular Diseases
Renmin Hospital of Wuhan University
Not applicable
200
Huangshi, Jingzhou, Wuhan, Xiangyang, Yichang
2026-05-20
Recruiting
Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction
NCT07587294Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)
Renmin Hospital of Wuhan University
Not applicable
100
Huangshi, Jingzhou, Shiyan, Wuhan, Xiangyang
2026-05-15
Not yet open
Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites
NCT07475715Allergic Rhinitis Due to Dust Mite
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497Non-small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Durvalumab
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Active, closed
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07424144Chronic Rhinosinusitis With Nasal Polyps
DrugItepekimab
Sanofi
Phase 3
59
Baotou, Beijing, Chengdu, Jingzhou, Shenyang, Taiyuan
2026-03-12
Active, closed
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788Hypertriglyceridemia
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Phase 2
40
Daqing, Harbin, Luoyang, Jingzhou, Nanyang, Yuncheng, Beijing
2026-02-28
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Beijing, Chongqing, Fuzhou, Jiangmen, Anyang, Luoyang, Jingzhou, Wuhan
2025-11-05
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hangzhou, Jinan, Jingzhou
2025-10-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
DrugsBNT324·Pumitamig
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Recruiting
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
NCT07128186Cognitive Dysfunction
Tongji Hospital
Observational
5,000
Enshi, Huanggang, Huangshi, Jingzhou, Shiyan, Suizhou, Wuhan, Xiangyang
2025-04-22
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
Remote Anxiety Management for ICS-resistant Asthma Study
NCT06732141Asthma
First Affiliated Hospital of Ningbo University
Not applicable
216
Harbin, Hefei, Jingzhou, Ningbo, Ninghai, Taizhou
2024-12-13
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Thumbtack Needle in the Treatment of NVP
NCT06566274Nausea and Vomiting in Pregnancy (NVP)
Dongmei Huang
Not applicable
320
Jingzhou, Nanzhang Chengguanzhen, Qianjiang, Shiyan, Suizhou, Wuhan, Xiangyang, Xiaogan
2024-10-01
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLY3650150
Eli Lilly and Company
Phase 3
450
Beijing, Changsha, Guangzhou, Hangzhou, Jingzhou, Nanchang, Nanning, Shanghai
2024-04-26
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
DrugGR1802
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06345365Acute Myeloid Leukaemia
Zhongnan Hospital
Phase 3
154
Zhengzhou, Huanggang, Jingzhou, Shiyan, Wuhan, Xianning, Xiaogan, Yichang
2024-01-18
Active, closed
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
NCT05879055Neuroendocrine Neoplasm
DrugsFolfiri·Pumitamig
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/jingzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in Jingzhou.

How many clinical trials are recruiting in Jingzhou?

14 of the 26 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jingzhou), 26 studies
PhaseStudiesRecruitingShare
Phase 39334.6%
Phase 27226.9%
Not applicable4415.4%
Observational227.7%
Phase 1/2217.7%
Phase 2/3113.8%
Phase 4113.8%

Most active sponsors

Lead sponsors with the most studies (Jingzhou)
Lead sponsorStudiesRecruiting
Sanofi41
Bristol-Myers Squibb22
Renmin Hospital of Wuhan University22
Beijing InnoCare Pharma Tech Co., Ltd.11
BioNTech SE11
Biotheus Inc.10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.10
Dongmei Huang11
Eli Lilly and Company10
First Affiliated Hospital of Ningbo University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.